OverviewSuggest Edit

LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient’s lymph nodes to be used as bioreactors to regrow functioning ectopic organs. The Company's lead preclinical program is focused on liver regeneration for patients with end stage liver disease.
TypePrivate
Founded2017
HQPittsburgh, PA, US
Websitelygenesis.com

Latest Updates

Employees (est.) (Apr 2022)6
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at LyGenesis

Michael Hufford

Michael Hufford

CEO
Paulo Fontes

Paulo Fontes

Chief Medical Officer
Eric Lagasse

Eric Lagasse

Chief Scientific Officer
Show more

LyGenesis Office Locations

LyGenesis has an office in Pittsburgh
Pittsburgh, PA, US (HQ)
1710 Murray Ave #200
Pittsburgh, PA, US
Shady Ave
Show all (2)

LyGenesis Financials and Metrics

Summary Metrics

Founding Date

2017

LyGenesis total Funding

$7 m

LyGenesis latest funding size

$4 m

Time since last funding

3 years ago

LyGenesis investors

LyGenesis's latest funding round in October 2019 was reported to be $4 m. In total, LyGenesis has raised $7 m
Show all financial metrics

LyGenesis Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

LyGenesis Online and Social Media Presence

Embed Graph

LyGenesis News and Updates

LyGenesis Announces a New Peer-Reviewed Publication Expanding its Liver Regeneration Technology

PITTSBURGH, Jan. 20, 2022 /PRNewswire/ -- LyGenesis, a clinical-stage biotechnology company developing cell therapies for patients with end stage liver disease, Type 1 diabetes, end stage renal disease, single enzyme deficiencies, and aging, announced today the publication of a new...

LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease, and also Closes $11 Million Convertible Debt Financing

PITTSBURGH, Dec. 30, 2020 /PRNewswire/ -- LyGenesis, Inc., a biotechnology company developing cell therapies that enable organ regeneration, announced today that the U.S Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application. Under the IND, LyGenesis...

LyGenesis Announces Four Peer-Reviewed Publications on its Organ Regeneration Technology

PITTSBURGH, Aug. 27, 2020 /PRNewswire/ -- LyGenesis, Inc., a biotechnology company focused on regenerative medicine, announced today that four peer-reviewed papers have been published on its organ regeneration technology. LyGenesis' lead development asset is liver regeneration, which was...

LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration Technology

PITTSBURGH, Oct. 21, 2019 /PRNewswire/ -- LyGenesis, Inc., a biotechnology company focused on organ regeneration, announced today that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, Ltd. and Longevity Vision Fund. Their technology...

LyGenesis Blogs

LyGenesis adds orphan paediatric indications with large unmet needs to its drug development pipeline with novel approach which first aims to treat pediatric patients with Maple syrup urine disease

LyGenesis, a clinical-stage biotechnology company developing cell therapies for patients with end stage liver disease, Type 1 diabetes, end stage renal disease and aging, announced today that it has achieved positive in vitro results of a novel combination drug-biologic product for patients with inb…

The Incrementalist Interview:

Listen in to hear Michael share the exciting progress to data that has taken the human bio-reactor of lymph nodes, something that is hijacked for use by cancer cells and instead use it for good to generate liver, and in the future, pancreas, thymus and kidney. Delivering multiple organ transplan…

LyGenesis’ FDA phase 2a clearance and $11m funding boost

Double bubble for biotech LyGenesis as it announces trial of its cell therapy for patients with end-stage liver disease, and closure of $11m convertible debt financing

Significant organ regeneration study progress for LyGenesis

Good news for organ regeneration as LyGenesis announces four peer-reviewed publications on its tech.Four peer-reviewed papers cover LyGenesis’ work on liver and kidney regeneration on an ectopic basis. Being able to move away from long transplants lists towards purpose-grown, histocompatible organs …
Show more

LyGenesis Frequently Asked Questions

  • When was LyGenesis founded?

    LyGenesis was founded in 2017.

  • Who are LyGenesis key executives?

    LyGenesis's key executives are Michael Hufford, Paulo Fontes and Eric Lagasse.

  • How many employees does LyGenesis have?

    LyGenesis has 6 employees.

  • Who are LyGenesis competitors?

    Competitors of LyGenesis include ENTEROME Bioscience, Precise Bio and Winnoz Technology.

  • Where is LyGenesis headquarters?

    LyGenesis headquarters is located at 1710 Murray Ave #200, Pittsburgh.

  • Where are LyGenesis offices?

    LyGenesis has an office in Pittsburgh.

  • How many offices does LyGenesis have?

    LyGenesis has 2 offices.